Aysun Soysal

Prof. Dr. Aysun Soysal

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
EBEdward De Brouwer
Edward De Brouwer
TBThijs Becker
Thijs Becker
YMYves Moreau
Yves Moreau
EHEva Kubala Havrdova
Eva Kubala Havrdova
MTMaria Trojano
Maria Trojano
LPLiesbet Peeters
Liesbet Peeters

27 January 2011 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
ASAysun Soysal
Aysun Soysal
FAF. Aysal
F. Aysal
BCB. Calıskan
B. Calıskan
PAP. Dogan Ak
P. Dogan Ak
BMB. Mutluay
B. Mutluay
BAB. Arpacı
B. Arpacı
To assess correlation between the prognosis and epidemiological, clinical, laboratory, electrophysiological findings in patients with Guillain-Barré syndrome (GBS). We reviewed the medical records of 104 GBS patients who were hospitalized and followed up at our outpatient clinic during October 1997-November 2007. Guillain-Barré syndrome patients were followed up with a median period of 232 days. Full recovery or minor deficits were observed in 41% of patients in the first month, 71% in the third month, 86% in the sixth month and 92% in the first year. We found that there was a correlation between Medical Research Council (MRC) sum scores at admission, clinical subtypes, respiratory distress, interference pattern and prognosis. Demographic, clinical and electrophysiological findings of our GBS cases were highly similar to those of the previous reports. Two of our cases were presented with preceding tuberculosis infection, which was not reported before in the literature.

25 July 2024 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
EBEdward De Brouwer
Edward De Brouwer
TBThijs Becker
Thijs Becker
LWLorin Werthen-Brabants
Lorin Werthen-Brabants
PDPieter Dewulf
Pieter Dewulf
DIDimitrios Iliadis
Dimitrios Iliadis
LPLiesbet Peeters
Liesbet Peeters
Background: Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the level of trust needed to be adopted in the clinic. A common benchmark to assess model development in multiple sclerosis is also currently lacking. Methods: Data of adult PwMS with a follow-up of at least three years from 146 MS centers, spread over 40 countries and collected by the MSBase consortium was used. With basic inclusion criteria for quality requirements, it represents a total of 15, 240 PwMS. External validation was performed and repeated five times to assess the significance of the results. Transparent Reporting for Individual Prognosis Or Diagnosis (TRIPOD) guidelines were followed. Confirmed disability progression after two years was predicted, with a confirmation window of six months. Only routinely collected variables were used such as the expanded disability status scale, treatment, relapse information, and MS course. To learn the probability of disability progression, state-of-the-art machine learning models were investigated. The discrimination performance of the models is evaluated with the area under the receiver operator curve (ROC-AUC) and under the precision recall curve (AUC-PR), and their calibration via the Brier score and the expected calibration error. All our preprocessing and model code are available at https://gitlab.com/edebrouwer/ms_benchmark, making this task an ideal benchmark for predicting disability progression in MS. Findings: Machine learning models achieved a ROC-AUC of 0⋅71 ± 0⋅01, an AUC-PR of 0⋅26 ± 0⋅02, a Brier score of 0⋅1 ± 0⋅01 and an expected calibration error of 0⋅07 ± 0⋅04. The history of disability progression was identified as being more predictive for future disability progression than the treatment or relapses history. Conclusions: Good discrimination and calibration performance on an external validation set is achieved, using only routinely collected variables. This suggests machine-learning models can reliably inform clinicians about the future occurrence of progression and are mature for a clinical impact study.

1 December 2014 in Clinical Neurophysiology
Verified
Journal Article
Closed access
HSHande Sariahmetoglu
Hande Sariahmetoglu
ASAysun Soysal
Aysun Soysal
ASAysu Sen
Aysu Sen
BYBurcu Yuksel
Burcu Yuksel
SCSibel Celiker
Sibel Celiker
BABaki Arpaci
Baki Arpaci

1 October 2015 in The Neurologist
Verified
Journal Article
Closed access
AAAyse Altintas
Ayse Altintas
RKRana Karabudak
Rana Karabudak
BBBelgin P. Balci
Belgin P. Balci
MTMurat Terzi
Murat Terzi
ASAysun Soysal
Aysun Soysal
ASAksel Siva
Aksel Siva
Neuromyelitis optica (NMO) is an immune-mediated, chronic relapsing, inflammatory disease characterized by severe attacks of optic neuritis and myelitis. To determine the demographic, clinical, and laboratory features; antibody status; and treatment modalities of patients with NMO and neuromyelitis optica spectrum disorders in a Turkish cohort from 11 centers. A total of 182 patients were included in this study. Data on age at disease onset, sex, type of attacks, clinical presentation, analysis of cerebrospinal fluid, serum antiaquaporin-4 antibody status, annual progression index, and medical and family histories were collected. Mean age was 38.43±12.40 years (range, 13 to 75 y), and mean age at disease onset was 31.29±12.40 years (median, 29 y; range, 10 to 74 y). In NMO group, the rate of NMO immunoglobulin (Ig)G positivity was 62.5%. The annual progression index was significantly higher in the longitudinally extending spinal cord lesion. The mean Expanded Disability Status Scale score was higher in the late than early-onset NMO group. Our results revealed a lower rate of NMO IgG positivity, more severe disability in patients with NMO/neuromyelitis optica spectrum disorders presenting with either transverse myelitis or late-onset NMO, and no correlation between disability and NMO IgG status.

1 October 2008 in The Neuroradiology Journal
Verified
Journal Article
Closed access
ASAysun Soysal
Aysun Soysal
PDP. Dogan
P. Dogan
CDC. Dayan
C. Dayan
BCB.G. Caliskan
B.G. Caliskan
BAB. Arpaci
B. Arpaci
We describe the magnetic resonance imaging (MRI) findings in two patients admitted to our institution with neuropsychiatric symptoms and severe abdominal pain diagnosed as acute intermittent porphyria (AIP). MRI revealed multiple lesions which regressed following treatment. We suggest reversible cerebral vasospasm underlies the MRI abnormalities and the cerebral symptoms in porphyria.